Inozyme Pharma's total assets for Q3 2024 were $143.36M, a decrease of -7.93% from the previous quarter. INZY total liabilities were $60.57M for the fiscal quarter, a -1.17% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.